Pfizer (PFE.N) this week forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism from activist hedge fund Starboard Value.
Shares of Pfizer rose about 2 per cent in premarket trading after the drugmaker also said it was expecting 2025 sales of its COVID-19 vaccine and drug to be consistent with 2024 levels.
The company expects
